Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
When HIV infects a CD4 cell in a person's body, it copies its own genetic code into the cell's DNA. In this way, the cell is then "programmed" to create new copies of HIV. HIV's genetic material is in the form of RNA. In order for it to infect CD4 cells, it must first convert its RNA into DNA. HIV's reverse transcriptase enzyme is needed to perform this process.
NNRTIs, also known as "non-nucleosides" or "non-nukes" for short, attach themselves to reverse transcriptase and prevent the enzyme from converting RNA to DNA. In turn, HIV's genetic material cannot be incorporated into the healthy genetic material of the cell, and prevents the cell from producing new virus.
*generic or biosimilar available
E experimental
DRUG Edurant |
---|
|
GENERIC NAME rilpivirine |
COMPANY Janssen Therapeutics |
DRUG Intelence |
---|
|
GENERIC NAME etravirine |
COMPANY Janssen Therapeutics |
DRUG Pifeltro |
---|
|
GENERIC NAME doravirine |
COMPANY Merck & Company |
DRUG Rescriptor |
---|
|
GENERIC NAME delavirdine |
COMPANY ViiV Healthcare |
DRUG Sustiva* |
---|
|
GENERIC NAME efavirenz |
COMPANY Bristol-Myers Squibb |
DRUG Viramune and Viramune XR* |
---|
|
GENERIC NAME nevirapine |
COMPANY Boehringer-Ingelheim |